Medicine injection devices, systems, and methods for medicine administration and tracking

    公开(公告)号:US11904146B2

    公开(公告)日:2024-02-20

    申请号:US17342449

    申请日:2021-06-08

    CPC classification number: A61M5/31568 A61M2205/18 A61M2205/3306 A61M2205/52

    Abstract: A medicine delivery and tracking system includes a medicine injection pen and a delivery port. The pen includes a needle through which medicine is dispensed and an electronic unit configured to at least one of log dispensing of medicine from the pen, control dispensing of medicine from the pen, or communicate regarding dispensing of medicine from the pen. Alternatively, the electronic unit may be part of a separate computing device. The delivery port is configured for attachment to a user and to receive the needle of the pen such that medicine dispensed from the pen is dispensed into the delivery port and through the delivery port to the user. The delivery port includes a detector mechanism configured to detect a presence of the pen and, in response thereto, to communicate a signal to the electronic unit for use in the at least one of logging, controlling, or communicating.

    IN-SITU CHEMISTRY STACK FOR CONTINUOUS GLUCOSE SENSORS

    公开(公告)号:US20170315077A1

    公开(公告)日:2017-11-02

    申请号:US15141446

    申请日:2016-04-28

    Abstract: Embodiments of the invention provide an in-situ polymerization technique for creating a glucose sensor chemistry stack. An analyte sensor comprises a crosslinked polymer matrix in contact with an electrode. The crosslinked polymer matrix is formed by exposing ultraviolet (UV) light to a polymer matrix mixture comprising a plurality of hydroxyethyl methacrylate (HEMA) monomers, one or more di-acrylate crosslinkers, one or more UV photoinitiators, and an oxidoreductase. The oxidoreductase is covalently linked to the crosslinked polymer matrix. In typical embodiments, the oxidoreductase is a glucose oxidase-acrylate bioconjugate. In one or more embodiments, the analyte sensor apparatus further comprises a glucose limiting membrane positioned over the crosslinked polymer matrix. The glucose limiting membrane is formed by exposing ultraviolet (UV) light to a glucose limiting membrane mixture comprising a plurality of hydroxyethyl methacrylate (HEMA) monomers, one or more di-acrylate crosslinkers, one or more UV photoinitiators, ethylene glycol, and water.

Patent Agency Ranking